enfortumab vedotin

Enfortumab Vedotin-Induced Cutaneous Toxicity: A Marker of Improved Survival in Advanced Urothelial Carcinoma

By MedXY 08/07/2026

Enfortumab vedotin (EV) therapy in advanced urothelial carcinoma is frequently associated with cutaneous adverse events (cAEs). These EV-induced skin toxicities correlate independently with improved progression-free and overall survival, even after adjusting for confounders like immune checkpoint inhibitor use.

news Oncology Urology

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

By MedXY 02/22/2026

The Phase 3 KEYNOTE-905/EV-303 trial demonstrates that perioperative enfortumab vedotin plus pembrolizumab significantly improves event-free survival (HR 0.40) and overall survival (HR 0.50) compared to surgery alone in cisplatin-ineligible patients with muscle-invasive bladder cancer.

news Oncology

AUC3 2025: Expert Consensus Roadmap for Renal Cell and Urinary Tract Cancer Care

By MedXY 12/19/2025

The 2025 Advanced Urologic Cancer Consensus Conference (AUC3) issues practical, evidence‑informed expert recommendations on diagnosis, perioperative therapy, frontline and later‑line systemic sequencing, and special populations for RCC and urinary tract cancers.

Clinical Updates news Oncology Specialties Urology

Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer: Patient-Reported Outcomes from the EV-302 Phase 3 Study

By MedXY 08/03/2025

The EV-302 trial shows enfortumab vedotin plus pembrolizumab improves survival and quality of life over platinum-based chemotherapy in untreated advanced urothelial cancer patients.